6TH World Congress of Cutaneous Lymphomas

JUNE 25-27, 2026

Montréal

www.6WCCL.org

As of April 20, 2026

Wednesday, June 24, 2026	11:00–13:00		
	13:00–14:00	**USCLC Board Meeting** [by invitation] *McGill*	
	14:00–15:30	**ISCL Board Meeting** [by invitation] *Ramzay*	
	15:00–18:00	**REGISTRATION opens** *Montreal Ballroom Foyer*	
	15:30–16:30	**EORTC Board Meeting** [by invitation] *McGill*	
	16:30–18:30		
	19:00–21:30	**ISCL Board of Directors Dinner** [by invitation] *Offsite – L'Auberge Saint-Gabriel*	

Thursday, June 25, 2026

06:30–17:00	**REGISTRATION**	
07:00–08:00	**CONTINENTAL BREAKFAST AND POSTER VIEWING IN EXHIBIT HALL** *Grande Place (8th Floor)*	
08:15–08:30	**Welcome & Announcements** *Montreal Ballroom*	
08:35 – 10:00	**Session 1A – New biomarkers for predicting outcome in CTCL** *Montreal Ballroom* Primary Chair: Steven Horwitz Co-Chairs: Maxime Battistella, Alison Moskowitz	**Session 1B - From Novel Topicals to Real-world Outcomes** *Fortifications Ballroom* Primary Chair: Tomomitsu Miyagaki Co-Chairs: Antonio Cozzio, Julia Dai
Session Learning Objectives:	At the end of this session, participants will be able to: 1. Apply new biomarkers to understanding of prognosis in CTCL 2. Clarify relationship of dupilumab and risk of CTCL progression	At the end of this session, participants will be able to: 1. Apply emerging clinical trial data on novel topical therapies to the management of early-stage cutaneous T-cell lymphoma. 2. Analyze long-term clinical trajectories and relapse patterns in indolent B-cell lymphomas and CD4+ LPD based on large-scale cohort studies and real-world evidence. 3. Identify key risk factors and complications, such as second primary malignancies and folliculotropism, to improve long-term survivorship care.
08:35	Introduction – *Steven Horwitz*	Introduction – *Tomomitsu Miyagaki*
08:40	Evaluation of TRBC1 immunohistochemistry versus high-throughput sequencing of TCRB gene for clonality assessment in cutaneous T-cell lymphomas *Andy Li,* Service de Dermatologie, Hôpital Saint-Louis, APHP, *Paris,* France	Interim Results for FLASH2: A Confirmatory Phase 3 Study of Topical HyBryte™ Activated by Visible Light for Cutaneous T-Cell Lymphoma *Ellen J. Kim,* Perelman School of Medicine at the University of Pennsylvania, *Philadelphia,* USA
08:50	Unraveling the nature of T-cell clones of uncertain significance in cutaneous T-cell lymphomas *Safa Najidh, Stanford University, Palo Alto, USA*	A pilot study to assess safety and efficacy of tofacitinib 2% cream in the treatment of early-stage mycosis fungoides *Julia Dai,* University of Texas MD Anderson Cancer Center, Houston, USA
09:00	The Genomic Landscape of Mycosis Fungoides: Therapy-Associated UV Mutagenesis and Oncogenic JUNB A282V Mutation *Pan Lai,* Peking University First Hospital, Beijing, China	Treatment Outcomes and Frequent Relapsers in Primary Cutaneous Indolent B-Cell Lymphomas: A 213-Patient Single-Center Cohort Study *Silvia Alberti-Violetti,* University of Milan, *Milan,* Italy
09:10	Distinct Molecular Signatures as Predictors of Early Mortality in Advanced Mycosis Fungoides *Pablo L. Ortiz-Romero,* Hospital Universitario 12 de Octubre, *Madrid,* Spain	Folliculotropism and Infection-Associated Outcomes in Cutaneous T-Cell Lymphoma *Toan Bui,* Johns Hopkins University, Baltimore, USA
09:20	Head and Neck Lesions as Sentinel Clinical Features of Dupilumab-Associated Cutaneous T Cell Lymphoma - *Yu Xiao,* Peking University First Hospital, Beijing, China	The risk of developing second primary malignancies in patients with cutaneous lymphomas *Lauren Banner,* Thomas Jefferson University, Philadelphia, USA
09:30	Dupilumab Accelerates T-Cell Lymphoma via A20-Deficient NF-kB Signaling and STAT3/5 Amplification - *Mingjia Li,* Peking University First Hospital, Beijing, China	Real-world outcomes of primary cutaneous $CD4^+$ small/medium T-cell lymphoproliferative disorder in a UK supra-regional cutaneous lymphoma centre *Neenu Sebastian,* University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

	09:40	Loss of fibroblast interaction with malignant T-cell clones is associated with aggressive CTCL behavior across CD4+, CD8+ and TCR-γδ+ malignant phenotypes *Abigail Fleischli,* Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, USA	Clinical Outcomes in Primary Cutaneous Peripheral T-cell Lymphoma, Not Otherwise Specified *Robert Stuver, Memorial Sloan Kettering Cancer Center, New York, USA*
Thursday, June 25, 2026	09:50	Q&A / Panel Discussion	Q&A / Panel Discussion
	10:00-10:40	**MORNING BREAK AND POSTER VIEWING IN EXHIBIT HALL** *Grande Place (8th Floor)*	
	10:40 – 12:00	**Session 2 – Risk, Disparities, and Prognostic Determinants in Cutaneous T-Cell Lymphoma** *Montreal Ballroom* Primary Chair: Larisa Geskin Co-Chairs: Pamela B. Allen, Sima Rozati	
	Learning Objectives:	At the end of this session, participants will be able to: 1. Identify clinical and biologic high-risk features in early-stage mycosis fungoides and Sézary syndrome. 2. Analyze racial, ethnic, and socioeconomic disparities affecting diagnosis, disease severity, and outcomes in CTCL. 3. Apply emerging diagnostic and biologic tools to improve risk stratification and promote equitable care in patients with CTCL.	
	10:40	Introduction – *Larisa Geskin*	
	10:45	Identifying High-Risk Early-Stage Mycosis Fungoides: Prognostic Insights from the PROCLIPI Cohort *Julia J. Scarisbrick,* University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom	
	10:55	Racial Differences in Prognosis in Mycosis Fungoides and Sézary Syndrome: Analysis from the BEACON (Building an Equitable and Collaborative Oncology Network)-CTCL Cohort *Pamela B. Allen,* Winship Cancer Institute of Emory University, Atlanta, USA	
	11:05	Colour Lines in Cancer? Exploring race as determinant of Cutaneous T-Cell Lymphoma outcomes, using the global PROCLIPI cohort *Abraham E. Bashir,* University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom	
	11:15	Racial and Ethnic Disparities in T-Cell Receptor Beta Repertoire in Cutaneous T-Cell Lymphoma *Liliana L. Crisan,* City of Hope Comprehensive Cancer and Beckman Research Institute, Duarte, USA	
	11:25	Bridging Racial Disparities in Mycosis Fungoides Diagnosis Through Dermoscopy *Hadar K. Shimshon,* Downstate University of New York Downstate Health Sciences University, New York, USA	
	11:35	Mycosis Fungoides in the Pediatric Population in Chile: A Retrospective Study *Rocío Millán, Pontificia Universidad Católica de Chile, Santiago, Chile*	
	11:45	Area Deprivation and Disease Severity in Adult Patients with Cutaneous T-Cell Lymphoma *Kofi Owusu-Ansah,* University of Wisconsin, Madison, USA	
	11:55	Q&A / Panel Discussion	
	12:05–13:20	***Accredited Symposium:*** **The Importance of Durability of Response in Managing CTCL** *Co-developed with Therakos LLC* *Lunch served* *Fortifications Ballroom*	**LUNCH AND POSTER VIEWING IN EXHIBIT HALL** *Grande Place (8th Floor)*
	13:30-14:20	**Plenary:** Herschel S. Zackheim Lectureship **40 Years of Research on Skin Immunity** – *Thomas Kupper* *Montreal Ballroom* Primary Chairs: Julia Scarisbrick, Steven Horwitz	

Thursday, June 25, 2026			
	14:30 – 15:50	**Session 3A – T cells Gone Rogue: Single-Cell, Spatial, and Molecular Frontiers in CTCL** *Montreal Ballroom* Primary Chair: Joan Guitart Co-Chairs: Adele de Masson, Robert Gniadecki	**Session 3B - Optimizing Mogamulizumab Therapy in Cutaneous T-Cell Lymphomas: Real-World Evidence, Safety, and Long Term Outcomes** *Fortifications Ballroom* Primary Chair: Pietro Quaglino Co-Chairs: Barbara Pro, Kevin Imrie, Shamir Geller
	Learning Objectives:	At the end of this session, participants will be able to: 1. Describe the lesion-specific immune, stromal, and microbiomic landscapes of Mycosis Fungoides as revealed by single-cell proteomic, transcriptomic, and multi-omics approaches. 2. Integrate emerging data on T-cell clonal dynamics, checkpoint-dominated microenvironments, and immunosuppressive mechanisms to better understand disease progression and treatment response in CTCL. 3. Apply novel biomarkers and AI-based tools — including deep-learning T-cell recognition and molecular profiling of treatment-exposed lesions — to inform prognosis and therapeutic decision-making in Mycosis Fungoides.	At the end of this session, participants will be able to: 1. Evaluate real-world and on the effectiveness of mogamulizumab in patients with mycosis fungoides and Sézary syndrome, including comparative outcomes versus clinical trial evidence and standard therapies. 2. Assess management strategies associated with mogamulizumab treatment, including retreatment following adverse events such as drug-related rash. 3. Interpret long-term outcomes and treatment sequencing strategies, including discontinuation and retreatment approaches, to inform clinical decision-making in relapsed or refractory disease.
	14:30	Introduction – *Joan Guitart*	Introduction – *Pietro Quaglino*
	14:35	Single-cell proteomic and transcriptomic profiling of lesion-specific aberrant T cell states and checkpoint-dominated microenvironment of Mycosis Fungoides *Eleni-Kyriaki Vetsika,* Department of Basic and Clinical Sciences, Medical School, University of Nicosia, UNIC Athens, Greece	Real-world use of Mogamulizumab: final analysis of the "FIL-MOGA" study by the Italian Lymphoma Foundation (FIL) *Gabriele Roccuzzo,* Department of Medical Sciences, Section of Dermbritology, University of Turin, Italy
	14:45	Deep-learning based T-cell Recognition and Automated Clone Estimation in early-stage Mycosis Fungoides: a proof of concept study (TRACE-MF) *Pieter A. Valkema,* Leiden University Medical Center, Leiden, Netherlands	Patients with Mogamulizumab-associated rash can be safely retreated with Mogamulizumab with durable remissions: A single center experience *Amy Liao,* Washington University School of Medicine, St. Louis, USA
	14:55	Single-cell profiling of advanced-stage mycosis fungoides reveals distinct immune and stromal responses in tumor versus erythrodermic lesions *Patrick Brunner,* Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, USA	"Moga-Stop" Study: extended follow-up of patients with Sézary syndrome treated with mogamulizumab after treatment discontinuation, excluding for progression *Marie Beylot-Barry,* CHU Bordeaux, *Bordeaux Cedex,* France
	15:05	Integrated Transcriptomic and Microbiomic Profiling of Keratinocytes in Erythrodermic Cutaneous T-cell Lymphoma Identifies Distinct Epidermal-microbial Patterns *Katherine De Jong,* Northwestern University, Chicago, USA	Overall survival in patients with mycosis fungoides or Sézary syndrome in Denmark: comparative effectiveness of mogamulizumab versus standard of care *Lena Specht,* Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
	15:15	The Role of CD84 (SLAMF5) in the Immunosuppressive Tumor Microenvironment of CTCL *Laura C. Schultz,* Division of Dermatology, City of Hope, Duarte, USA	Outcomes in relapsed/refractory mycosis fungoides or Sézary syndrome from the MAVORIC trial mogamulizumab arm versus a real-world Australian cohort receiving vorinostat *H. Miles Prince,* Peter MacCallum Cancer Centre, Melbourne, Australia
	15:25	Lesion-specific immune and clonal reprogramming drives Chlormethine gel response and treatment-associated dermatitis in Mycosis Fungoides	**15:25 – 15:30** – Q&A / Panel Discussion

Thursday, June 25, 2026			
		Evangelia Papadavid, Centre of Excellence for Rare Diseases-Cutaneous Lymphoma, ERN-EuroBloodNet, Second Department of Dermatology and Venereal Diseases, Attikon University General Hospital, National and Kapodistrian University of Athens, Greece	
	15:35	Molecular analysis of irradiated cutaneous T-cell lymphoma tumors suggests markers associated with response and risk of recurrence *Eleanor Ostroff,* Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, USA	
	15:45	Q&A / Panel Discussion	
			15:40 – 17:20 **Session 4B – Integrating immune profiling with genomics to predict therapy response** *Fortifications Ballroom* Primary Chair: Christiane Querfeld Co-Chairs: Alejandro Gru, Denis Miyashiro
	16:00 – 17:20	**Session 4A – Contemporary Advances in Cutaneous T-Cell Lymphomas'. New Frontiers in Cutaneous Lymphoma Diagnosis and Prognosis** *Montreal Ballroom* Primary Chair: Rudolf Stadler Co-Chairs: Neda Nikbakht, Swami Iyer	**Learning Objectives:** At the end of this session, participants will be able to: 1. Describe how immune profiling of blood and skin informs disease biology and treatment response in CTCL. 2. Integrate genomic and clonality-based biomarkers into assessment of disease burden and therapeutic monitoring. 3. Apply emerging biomarker strategies to predict and evaluate response to mogamulizumab and other targeted therapies in CTCL.
			15:40 - Introduction – *Christiane Querfeld*
	Learning Objectives	At the end of this session, participants will be able to: 1. Apply recent clinico-pathological and prognostic insights (e.g. lesional BSA thresholds, TFH phenotype, co-occurring lymphomas) to refine the diagnosis and risk stratification of cutaneous T-cell lymphomas in daily practice. 2. Integrate emerging tools, such as multiparameter flow cytometry, digital whole-slide image analysis and targeted genomics, to improve the classification and monitoring of primary cutaneous lymphomas. 3. Clarify how novel clinical entities and 'borderline' presentations beyond classical mycosis fungoides impact therapeutic decision-making and recommendations for patient follow-up.	15:45 - Functional Immune States of Blood and Skin Microenvironment Predict Mogamulizumab Response in Sézary Syndrome *Hélène Moins-Teisserenc,* IRSL-Université Paris Cité, Paris, France
	16:00	Introduction – *Rudolf Stadler*	15:55 - Targeted sequencing in patients with relapsed/refractory mycosis fungoides or Sézary syndrome treated with mogamulizumab in the MOGA-2MG-Q4W clinical trial *Christiane Querfeld,* City of Hope National Medical Center, Beckman Research Institute, Duarte, USA
	16:05	Presentation with confluent erythema not reaching 80% body surface area is associated with advanced stage disease and has worse outcome than classical MF in the early stages *Julia J. Scarisbrick,* University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom	Rapid and Durable Blood Remission in CTCL Using Mogamulizumab: B2 as a Surrogate Marker *Yenny Angela,* University Clinic of Dermatology, Venerology, Allergology und Phlebology Skincancer Center Johannes Wesling Medical Center, Ruhr University Bochum, Minden, Germany

Thursday, June 25, 2026			
	16:15	Cutaneous flow cytometry: 10 years of experience from a single center *Emmanuela Guenova,* Department of Translational Immunodermatology, Kepler University Hospital, Johannes Kepler University, Linz, Austria	Distinct genomic profiling of folliculotropic mycosis fungoides: integrated data of whole genome sequencing and single-cell spatial transcriptomics *Woo Jin Lee,* Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
	16:25	Reproducible Cohort Generation and Whole-Slide Learning for Cutaneous T-Cell Lymphoma and Related Lymphoproliferative Disorders *Melissa Pulitzer,* Memorial Sloan Kettering Cancer Center, New York, USA	Non-JAK-Family Gene Fusions in Cutaneous T-cell Lymphoma Highlights Genetic Diversity and Potential Therapeutic Targets *Haiming Tang,* Memorial Sloan Kettering Cancer Center, New York, USA
	16:35	Investigating the Genetic Landscape of Primary Cutaneous Lymphomas and Lymphoproliferative Disorders with T Follicular Helper Cell Phenotype (PCL-TFH) *Ziba Rahbar,* Brigham and Woman's Hospital, Harvard Medical School, Boston, USA	Evaluation of TRBC1-based Clonality to Quantitate Blood Involvement in Cutaneous T Cell Lymphoma *Katherine De Jong,* Northwestern University, Chicago, USA
	16:45	Co-occurring Chronic Lymphocytic Leukemia in Mycosis Fungoides/Sézary Syndrome: Retrospective Analysis *Julia Dai,* Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, USA	Characterization of adult T-cell leukemia/lymphoma patients with specific skin lesions in a tertiary dermatological service in Brazil *Denis Miyashiro,* Department of Dermatology, University of São Paulo Medical School, São Paulo, Brazil
	16:55	Non-alpha/beta T-cell lymphoma: a single Centre experience on gamma/delta and TCR-silent subsets Giorgio Alberto Croci, University of Milan, Milan, Italy	Baseline macrophage states determine immune reprogramming trajectories and clinical response to extracorporeal photopheresis in Sézary syndrome *Oleg Akilov,* University of Pittsburg School of Medicine, Pittsburg, USA
	17:05	Mycosis fungoides with a gamma-delta immunophenotype: do they differ from epidermotropic primary cutaneous gamma-delta T-cell lymphoma? *Eleanor B. Ostroff,* Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, USA	Molecular-based Reconsideration of Classification of Primary Cutaneous CD30-positive Lymphoproliferative Disorders *Yamato Suemitsu,* Memorial Sloan Kettering Cancer Center, New York, USA
	17:15	Q&A / Panel Discussion	Q&A / Panel Discussion
	17:30–18:30	**POSTER SESSION WALK IN EXHIBIT HALL** *Grande Place (8th Floor)* Primary Chair and Poster Walk Leader: Paula Enz	
	18:00–20:00	**WELCOME RECEPTION** *Grande Place (8th Floor)*	

Friday, June 26, 2026

06:30–17:00	**REGISTRATION**
07:00–08:00	**CONTINENTAL BREAKFAST AND POSTER VIEWING IN EXHIBIT HALL** *Grande Place (8th Floor)*
08:15-09:00	Plenary / Invited Speaker **Advances in Computational/Digital Pathology and AI in the Diagnosis of Cancer and Prediction of Prognosis** – *Jason Hipp* *Montreal Ballroom* Primary Chairs: Steven Horwitz, Julia Scarisbrick **Learning Objectives:** At the end of this session, participants will be able to:
09:05 – 10:15	**Session 5 – Cutaneous Lymphoma International Consortium: Together we can** *Montreal Ballroom* Primary Chair: Youn Kim Co-Chairs: Marie Beylot-Barry, Rein Willemze
Learning Objectives	At the end of this session, participants will be able to: 1. Appreciate that international collaborations are feasible and productive in generating large datasets in rare lymphomas 2. Recognize meaningful prognostic factors and treatment profiles and impact in CTCL utilizing international collective data
09:05	Introduction – *Youn Kim*
09:10	Building on CLIPI: Deeper Dive into Advanced Stage Subset *Youn Kim,* Stanford University, Stanford, *USA*
09:30	Treatment patterns in early-stage Mycosis Fungoides: a 10-Year update from the PROCLIPI study *Gabriele Roccuzzo,* Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy
09:40	Navigating Therapeutic Complexity in Advanced-Stage MF/SS: Real-World Insights from the PROCLIPI Study *Abraham E. Bashir,* University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
09:50	Blood Tumor Burden Refines Prognostication: Validation of PROCLIPI for Advanced Cutaneous Lymphoma in a Chinese Cohort *Zhuojing Chen,* Peking University First Hospital. Beijing, China
10:00	How Big Is Big Enough? The Potential for Imaging-derived Quantitative Thresholds for Identifying N3 Nodal Disease in CTCL using PROCLIPI *Abraham E. Bashir,* University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
10:10	Q&A / Panel Discussion
10:15-10:55	**MORNING BREAK AND POSTER VIEWING IN EXHIBIT HALL** *Grande Place (8th Floor)*

Friday, June 26, 2026

10:55 – 12:15	**Session 6 – Novel Targets for CTCL Treatments** *Montreal Ballroom* Primary Chair: Martine Bagot Co-Chairs: Michael Khodadoust, Auris Huen
Learning Objectives	At the end of this session, participants will be able to: 1. Identify and validate novel targets for the treatment of cutaneous T cell lymphoma. 2. Clarify the use of new treatments.
10:55	Introduction – *Martine Bagot*
11:00	Nivolumab with duvelisib leads to repeated immune-mediated toxicities in cutaneous T-cell lymphoma (CTCL): Clinical results of ETCTN Study 10347 *Neha Mehta-Shah,* Washington University in St. Louis, USA
11:10	Targeting TNFR2 with BI-1808: Immune Activation and Promising Responses in Advanced T-Cell Lymphomas – *Stefan Barta,* University of Pennsylvania Hospital, Philadelphia, USA
11:20	Dupilumab Use in Atopic Dermatitis When Cutaneous Lymphoma Is Suspected: Consensus Recommendations from the EORTC Cutaneous Lymphoma Task Force *Emmanuella Guenova,* Department of Translational Immunodermatology, Kepler University Hospital, Johannes Kepler University, Linz, Austria
11:30	Updated Clinical Data from the Phase 1 Study of Dibotatug (DR-01), a Non-Fucosylated Anti-CD94 Antibody in Patients with Relapsed/Refractory Cytotoxic T/NK cell Lymphomas *Swaminathan Iyer,* MD Anderson Cancer Center, Houston, USA
11:40	Mycosis fungoides-exosomes mediate reprogramming of tumor-associated macrophages via a novel mechanism of CD47- SIRPα checkpoint interaction *Lilach Moyal,* Rabin Medical Center and Tel-Aviv University, Petach Tikva, Israel
11:50	Preliminary results in a First-in-Human Trial of ST-001 nanoFenretinide in Previously Treated Cutaneous T-cell Lymphoma *Oleg Akilov,* University of Pittsburg School of Medicine, Pittsburg, USA
12:00	Cutaneous outcomes associated with nemolizumab use in patients with cutaneous T-cell lymphoma: a case series *Krithika Nayudu,* Medical College of Georgia, Augusta, USA
12:10	Q&A / Panel Discussion
12:15 – 12:30	**Award Session** *Montreal Ballroom* Primary Chair: Julia Scarisbrick Special Award Lifetime Achievement Award 1 Lifetime Achievement Award 2
12:30–13:55	**LUNCH AND POSTER VIEWING IN EXHIBIT HALL** *Grande Place (8th Floor)*
12:40-13:55	***Accredited Symposium:*** **Bridging the gap: Advancing diagnosis and management of CTCL through collaborative multidisciplinary care** *Co-developed with Kyowa Kirin* *Lunch served* *Fortifications Ballroom* **Learning Objectives:** By the end of this symposium, participants will be able to: • Recognize suspected CTCL by identifying diagnostic challenges and interpret the clinical and histopathological features of MF and SS using TNMB staging and diagnostic tools. • Outline effective referral pathways for suspected CTCL, enabling timely multidisciplinary collaboration while incorporating patient perspectives. • Apply multidisciplinary insights to assess disease and patient characteristics that inform CTCL management and treatment decisions.

Friday, June 26, 2026

14:05 – 15:20	**Session 7A – Young Investigators Presentations: Risk, Disparities, and Disease Behavior in Cutaneous Lymphomas** *Montreal Ballroom* Primary Chair: Oleg Akilov Co-Chairs: Jade Cury Martins, Montserrat Molgo	**Session 7B - "The Great Transformation": LCT and predicting CTCL outcomes** *Fortifications Ballroom* Primary Chair: Yang Wang Co-Chairs: Gizelle Popradi, Philippe Lefrancois
Learning Objectives:	At the end of this session, participants will be able to: 1. Describe epidemiologic risks and secondary malignancy patterns in patients with cutaneous lymphomas. 2. Recognize biologic and clinical factors, including microbial influences and phenotype, that contribute to disease severity and heterogeneity. 3. Interpret prognostic indicators across CTCL and related entities, including extracutaneous progression and transplant-related outcomes.	At the end of this session, participants will be a able to: 1. Describe clinical indicators of poor outcome and progression in CTCL 2. Define the clinical and molecular features of LCT
14:05	Introduction – *Oleg Akilov*	Introduction – *Yang Wang*
14:10	Risk of melanoma skin cancer among patients with mycosis fungoides and Sézary syndrome. A Swedish nationwide population-based cohort study. *Karolina Wojewoda,* Department Dermatology and Venereology, University of Gothenburg, Gothenburg, Sweden	Understanding The Molecular Triggers Of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) Progression *Fabio Ianelli,* Division of Hematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy
14:20	Staphylococcal Hemolysins Associated with Racial Disparities and Increased Clinical Severity in Cutaneous T-Cell Lymphoma *Amy S. Kaku,* Emory University School of Medicine, Department of Dermatology, Atlanta, USA	Large Cell Transformation in Mycosis Fungoides/Sezary Syndrome: Contemporary Outcomes, Predictors, and Disparities Signal from the U.S. BEACON-CTCL Cohort *Haris Qureshi,* Yale School of Medicine, New Haven, USA
14:30	Primary Cutaneous Marginal Zone Lymphoma developing extracutaneous disease: an European Organisation For Research And Treatment Cutaneous Lymphoma Tumour Group study. *Lindi Korpelshoek* Department of Dermatology, Leiden University Medical Center, Leiden, Netherlands	International study of mycosis fungoides with large-cell transformation confirms poor outcome and reveals heterogeneity in presentation, treatment and prognosis *Belinda A. Campbell.,* Peter MacCallum Cancer Centre, Melbourne, Australia
14:40	Disease status at HSCT, including skin-limited disease, and survival in BPDCN: A retrospective, multicenter cohort study of the EORTC, Cutaneous Lymphoma Tumour Group *Christoph Iselin,* Department of Dermatology, Lausanne University Hospital and Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland	Overall Survival in Transformed Mycosis Fungoides and Sezary Syndrome *Rishabh Lohray,* Baylor College of Medicine, Houston, USA
14:50	Characteristics and outcomes of cutaneous T-cell lymphoma with gamma-delta phenotype: A single-center case series *Stephanie K. Lin.,* Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, USA	Investigating the Utility of Baseline Imaging in Early-Stage Mycosis Fungoides: A retrospective analysis *Sarah M. Gonzalez,* Department of Dermatology, Dartmouth-Hitchcock Medical Center, Lebanon, USA
15:00	Understanding Patient Experiences and Quality of Life in Cutaneous T-Cell Lymphoma Through a Patient Education and Support Meeting *Brigit A. Lapolla,* Columbia University, New York, USA	Central nervous system involvement in mycosis fungoides and Sézary syndrome: multicenter series of 24 cases from French Cutaneous Lymphoma Study Group *Marie Beylot-Barry,* University Hospital Bordeaux, Bordeaux Cedex, France
15:10	Q&A / Panel Discussion	Q&A / Panel Discussion

Friday, June 26, 2026

15:30 – 16:30	**Session 8A – More Than Skin Deep: Patient Perspectives In Cutaneous Lymphoma** *Montreal Ballroom* Primary Chair: Julia Scarisbrick Co-Chairs: Elise Olsen, Constanze Jonak	
Learning Objectives	At the end of this session, participants will be able to: 1. Identify strategies to incorporate patient perspectives into clinical decision-making and care planning. 2. Recognize the importance of patient-centered care in the management of cutaneous lymphoma and how this may elevate patient quality of life.	
15:30	Introduction – *Julia Scarisbrick*	
15:35	Core Concepts to Assess Health-Related Quality of Life in Patients with Mycosis Fungoides and Sézary Syndrome in Clinical Trials: Results of two Electronic Delphi Rounds *Jenny J. Park,* Department of Dermatology, University of Washington, Seattle, USA	
15:45	Improved symptoms and health-related quality of life in patients with mycosis fungoides and Sézary syndrome treated with mogamulizumab in the PROSPER study *Julia J. Scarisbrick,* Centre for Rare Diseases, University Hospital of Birmingham, Birmingham, United Kingdom	
15:55	Using Skindex-29 and targeted instruments to assess the impact of patient factors on quality-of-life and diagnosis understanding over time in cutaneous lymphomas *Alyssa Wu,* City of Hope, Duarte, USA	**16:10 – 17:20** **Session 8B – Evolving Perspectives in Cutaneous T-Cell Lymphoma: From Traditional Histopathology to Advanced Diagnostic and Biological Insights** *Fortifications Ballroom* Primary Chair: Emmilia Hodak Co-Chairs: Melissa Pulitzer, Kevin Pehr
16:05	Patient-Reported Quality of Life Outcomes Following Extracorporeal Photopheresis for Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease. *Manda D. Mootien,* Guys and St Thomas, Great Maze Pond, United Kingdom	**Learning Objectives** At the end of this session, participants will be able to: 1. Understand new techniques for diagnosis of cutaneous T-cell lymphoma 2. Appreciate the complexity of cutaneous T- cell lymphoma and where diagnoses may overlap.
16:10		Introduction – Emmilia Hodak
16:15	Beyond Disease Control: Holistic Needs Assessment in Patients with Cutaneous Lymphoma in a Tertiary Skin Lymphoma Clinic *Amirtha Rajasekaran,* University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom	Reduced diversity in CTCL intratumoral microbiome is associated with JAK/STAT pathway alterations, non-European ancestry, and poor survival. *Paola Ghione,* Memorial Sloan Kettering Cancer Center, New York, USA

Friday, June 26, 2026

16:25	Q&A / Panel Discussion	Cytotoxic hyperactivation paired with vascular dysfunction and tissue hypoxia mediates lesion self-destruction in lymphomatoid papulosis *Patrick Brunner,* Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, USA
16:35		Multi-Harmonic Imaging-Based Automated Recognition of Cutaneous T-Cell Lymphoma *Yi-Chien Tsai,* Department of Dermatology and Venereology, University Hospital Centre (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
16:45		Geographic and temporal validation of a histopathology-based diagnostic prediction model for risk-stratified triage of early-stage mycosis fungoides *Anne M. Schrader,* Department of Pathology, Leiden University Medical Center, Leiden, Netherlands
16:55		Cutaneous anaplastic large cell lymphoma (ALCL): Clinical, histopathologic, molecular review of 13 cases of primary cutaneous ALCL & cutaneous involvement of systemic ALCL *Emma Johnson,* Mayo Clinic, Rochester, USA
17:05		Overlap: mycosis fungoides / Sezary syndrome and inflammatory dermatosis, a case series. *Giorgio Alberto Croci,* University of Milan, Milan, Italy
17:15		Q&A / Panel Discussion
17:30–18:30	**POSTER SESSION WALK IN EXHIBIT HALL** *Grande Place (8th Floor)* Primary Chair and Poster Walk Leader: Pablo Ortiz-Romero	
18:30–19:30	**Canadian Skin Lymphoma Network Board Meeting** [by invitation] *Fortifications*	
19:00-22:30	**GALA RECEPTION AND DINNER** Ticket purchase required *Montreal Ballroom*	

Saturday, June 27, 2026

07:00–15:00	**REGISTRATION**	
07:15 – 08:15	**CONTINENTAL BREAKFAST AND POSTER VIEWING IN EXHIBIT HALL** *Grande Place (8th Floor)*	
08:15 – 10:15	**Session 9A – Old Treatments Performing New Tricks** *Montreal Ballroom* Primary Chair: Francine Foss Co-Chairs: Alain Rook, David Roberge	**Session 9B – Patient Case Viewing and Discussions** *Fortifications Ballroom* Primary Chair: Ivan Litvinov Co-Chairs: Ellen Kim, Jasmine Zain, Amrita Goyal
Learning Objectives	At the end of this session, participants will be able to: 1. To describe the efficacy and adverse effects of available therapeutics in the treatment of cutaneous lymphomas 2. To understand the spectrum of use of some older therapeutics in the management of cutaneous T and B cell lymphomas	At the end of this session, participants will be able to:
08:15	Introduction – *Francine Foss*	Introduction – *Ivan Litvinov*
08:20	Long-term outcomes after allogeneic stem cell transplantation for cutaneous T-cell lymphoma *Samer A. Srour,* The University of Texas MD Anderson Cancer Center, Houston, USA	Clinical Spectrum and Diagnostic Challenges of Cutaneous T-Cell Lymphomas in Ghana: a Retrospective Analysis from a Tertiary Referral Center in Accra (2015–2024) *Prince Agyemang,* Eastern Regional Hospital, Koforidua, Ghana
08:30	Exploring the curative potential of allo-SCT in Cutaneous T-Cell Lymphoma *Julia J. Scarisbrick,* University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom	Ocular Mycosis Fungoides: A Single Center Case Series *Rishabh Lohray,* Baylor College of Medicine, Houston, USA
08:40	Interferon Alfa Lives on: Real-World Use and Safety of Pegylated Interferon Alfa-2a in Cutaneous T-Cell Lymphoma *Christina Cruz,* University of Pennsylvania, Philadelphia, USA	Recurrent bulky tumors in a post-allogeneic stem cell transplanted Mycosis Fungoides patient cleared with a single dose of pembrolizumab *Lauren Spadt,* University of Virginia School of Medicine, Charlottesville, USA
08:50	Clinical Outcomes and Durability of Localized Radiation Therapy Versus Topical Steroids in Stage IA Mycosis Fungoides *Sarah J. Lange,* Dartmouth Geisel School of Medicine, Hanover, USA	New recalcitrant perigenital tumor in the setting of otherwise well-controlled Sezary syndrome *Katherine De Jong,* Northwestern University, Chicago, USA
09:00	Systematic Review and Institutional Case Series of Intralesional Rituximab for the treatment of Primary Cutaneous B-cell Lymphoma *Jori Hardin,* University of Calgary, Division of Dermatology, Calgary, Canada	Epidermotropic cutaneous T-cell lymphoma with gamma delta immunophenotype: Four instructive cases *Jacqueline Junkins-Hopkins,* Geisinger Medical Center, Danville, USA
09:10	Hands and Feet Radiation Therapy for Cutaneous T-cell lymphoma *Ahmadou B. El Alaoui,* Memorial Sloan Kettering Cancer Center, New York, USA	Merkel Cell Carcinoma: A Cutaneous B-Cell Lymphoma in Disguise? *Ivan V. Litvinov,* St. Mary's Hospital Centre, McGill University, Montreal, Canada
09:20	The Therapeutic Potential of PDE4 Inhibitors in Mycosis Fungoides and Sézary Syndrome: A Brief In Vitro Study *Teruyoshi Hisamoto,* International University of Health and Welfare Hospital, Nasu-Shiobara City, *Japan*	Clinical Warburg Effect in a Primary Cutaneous Lymphoma *Emmanuella Guenova,* Department of Translational Immunodermatology, Kepler University Hospital, Johannes Kepler University, Linz, Austria

	09:30	Management of advanced mycosis fungoides and Sézary syndrome: international consensus recommendations from EHA, EORTC-CLTG, ISCL and EBMT *Pietro Quaglino,* Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy	Cutaneous CD8+ Cytotoxic Gamma-Delta T-cell Lymphoma Mimicking Angioedema *Eleanor B. Ostroff,* Northwestern University Feinberg School of Medicinem, Chicago, USA
Saturday, June 27, 2026	09:40	Linking CTCL cell biology with response to mogamulizumab for therapy optimization and identification of resistance mechanisms *Jan P. Nicolay,* University Medical Center Mannheim, Mannheim, Germany	Vulvar and Perianal CD8-Positive Lymphomatoid Papulosis: A Case for Interdisciplinary Management of Unknown Genital Lesions *Sarah M. Gonzalez,* Department of Dermatology, Dartmouth-Hitchcock Medical Center, Lebanon, USA
	09:50	Mapping the Spatial Immune Landscape in Sezary Syndrome: Insights into Moderate and Progressive Prognoses *Marie Chevalier,* Leiden University Medical Center, Leiden, Netherlands	CD8+ Primary Cutaneous Peripheral T-Cell Lymphoma in a 64-Year-Old Male: A Case Report and Diagnostic Insight *Karla Katrina T. Cajigal,* Jose R. Reyes Memorial Medical Center Department of Dermatology, Manila, Philippines
	10:00	Q&A / Panel Discussion	Q&A / Panel Discussion
	10:15-10:55	**MORNING BREAK AND POSTER VIEWING IN EXHIBIT HALL** *Grande Place (8th Floor)*	
	10:55 – 12:25	**Session 10 – Challenging Assumptions in Cutaneous Lymphomas: A Debate Series** *Montreal Ballroom* Primary Chairs: H. Miles Prince, Maarten Vermeer, Evangelia Papadavid	
	Learning Objectives	At the end of this session, participants will be able to: 1. Clarify evolving diagnostic boundaries in CTCL by examining expert debates on SPTCL classification, Sézary syndrome presentations, and pediatric CTCL evaluation. 2. Apply current evidence to differentiate challenging CTCL presentations, including blood involvement without erythroderma, in order to improve diagnostic accuracy and clinical decision-making. 3. Integrate prognostic indicators into the management of early-stage MF and evaluate whether treatment strategies should be modified at disease onset.	
	10:55	Introduction – TBC	
	11:00	Should SPTCL be classified as a lymphoma? - *Michael Girardi vs Joan Guitartt*	
	11:20	Pediatric CTCL: Are we underdiagnosing or overdiagnosing? - *Chalid Assaf*	
	11:40	Should we treat early MF with poor prognostic indicators differently from the onset? – *Jade Cury Martins vs. Maarten Vermeer*	
	12:00	Sézary syndrome without erythroderma as the initial presentation of a T-cell lymphoma. Is it a Mycosis fungoides debuting with stage B2 – *Emmilia Hodak, vs. Pablo Ortiz-Romero*	
	12:20	Final Q&A	
	12:25 – 12:55	**ISCL Assembly Meeting and Awards** *Montreal Ballroom*	

Saturday, June 27, 2026		
	12:55–13:55	**LUNCH AND POSTER VIEWING IN EXHIBIT HALL** *Montreal Ballroom Foyer*
	14:05 – 15:30	**Session 11 – Best of Congress** *Montreal Ballroom* Primary Chairs: Emmanuela Guenova, Jose Sanchez, Chalid Assaf
	Learning Objectives	At the end of this session, participants will be able to: 1. Summarize key advances and high-impact findings presented across multiple sessions of the Congress, as identified by expert Co-Chairs. 2. Integrate selected best-practice insights into clinical decision-making and future research directions in cutaneous lymphomas.
	14:05	Introduction –
	14:10-14:35	3 best sessions – *Emmanuela Guenova*
	14:35-15:00	3 best sessions – *Jose Sanchez*
	15:00-15:25	3 best sessions – *Chalid Assaf*
	15:25	Q&A / Panel Discussion
	15:30	Closing Remarks